Detalles de la búsqueda
1.
Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor.
Blood
; 142(1): 62-72, 2023 07 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36796019
2.
Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy.
Br J Clin Pharmacol
; 88(7): 3182-3192, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35029306
3.
Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study.
Lancet Oncol
; 22(10): 1468-1482, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34592180
4.
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial.
Lancet Oncol
; 21(1): 105-120, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31753727
5.
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial.
Lancet
; 390(10109): 2266-2277, 2017 Nov 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-28916371
6.
Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF).
Oncologist
; 23(12): 1407-e136, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-29853658
7.
MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping.
Invest New Drugs
; 36(4): 536-544, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29188469
8.
LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models.
Invest New Drugs
; 31(4): 833-44, 2013 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-23275061
9.
Outcomes for Patients With Chronic Lymphocytic Leukemia (CLL) Previously Treated With Both a Covalent BTK and BCL2 Inhibitor in the United States: A Real-World Database Study.
Clin Lymphoma Myeloma Leuk
; 23(1): 57-67, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36335022
10.
Clinical outcomes among patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who received treatment with a covalent BTK and BCL2 inhibitor in the United States: a real-world database study.
Leuk Lymphoma
; 64(5): 1005-1016, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36987650
11.
Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma.
J Clin Oncol
; 41(24): 3988-3997, 2023 08 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-37192437
12.
Outcomes among Patients with Mantle Cell Lymphoma Post-Covalent BTK Inhibitor Therapy in the United States: A Real-World Electronic Medical Records Study.
Adv Hematol
; 2022: 8262787, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36620778
13.
Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibility.
Blood
; 113(22): 5575-82, 2009 May 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-19299336
14.
Clinical development and evaluation of a VEGF-D assay in plasma from patients with metastatic colorectal cancer in the RAISE study.
Curr Med Res Opin
; 37(10): 1769-1778, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34229554
15.
A phase II study of 5-day intravenous azacitidine in patients with myelodysplastic syndromes.
Am J Hematol
; 84(9): 560-4, 2009 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-19650118
16.
LY2495655, an antimyostatin antibody, in pancreatic cancer: a randomized, phase 2 trial.
J Cachexia Sarcopenia Muscle
; 9(5): 871-879, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-30051975
17.
Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors.
Oncotarget
; 9(17): 13796-13806, 2018 Mar 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29568395
18.
A phase 1 study of the Janus kinase 2 (JAK2)V617F inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia.
Leuk Res
; 61: 89-95, 2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28934680
19.
Pharmacogenomic discovery approaches: will the real genes please stand up?
J Clin Oncol
; 23(29): 7342-9, 2005 Oct 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-16145062
20.
Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial.
J Clin Oncol
; 34(13): 1500-9, 2016 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26926681